The thing to watch for now ...IMHO is updates on enrollment in the Adult trial UpLift . They are probably being very selective on who they enroll. The risk with that is that it may take longer than planned to get to full enrollment and necessitate a capital raise ( small risk but not non existent ) . If the Adult UpLift trial succeeds they will use that data ...method of action etc ...combined hopefully with continuing good data from the pediatric trial ( more kids being able to drop other meds , no new adverse events etc ) to seek approval for the pediatric indication.
Thats your 5X to 10X price increase from here ...10X if both indications produce data by end of year ...that will lead to a high chance of eventual approval ... before need for a capital raise . High risk JMO Kiwi
Market Data 
Markets 
AI
